Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of DS-8201 in metastatic advanced breast cancer
ChiCTR2400093267Phase 4Recruiting
- Sponsor
- Beijing Chaoyang Sanhuan Cancer Hospital
- Start
- Dec 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab deruxtecan in breast cancer, sponsored by Beijing Chaoyang Sanhuan Cancer Hospital. Primary endpoint: Change in size of primary or metastatic lesions. Started Dec 2024; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400093267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093267.